SGLT2 inhibitors improved health status in Black and White patients with HF regardless of race

Ambarish Pandey; Harriette G C Van Spall

doi:10.7326/J23-0071

SGLT2 inhibitors improved health status in Black and White patients with HF regardless of race

Ann Intern Med. 2023 Sep;176(9):JC100. doi: 10.7326/J23-0071. Epub 2023 Sep 5.

Authors

Ambarish Pandey¹, Harriette G C Van Spall²

Affiliations

¹ UT Southwestern Medical Center, Dallas, Texas, USA (A.P.).
² McMaster University, Hamilton, Ontario, Canada (H.G.V.).

PMID: 37665988
DOI: 10.7326/J23-0071

Abstract

Gupta K, Spertus JA, Birmingham M, et al. Racial differences in quality of life in patients with heart failure treated with sodium-glucose cotransporter 2 inhibitors: a patient-level meta-analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF trials. Circulation. 2023;148:220-228. 37191040.

Publication types

Meta-Analysis
Comment

MeSH terms

Black People
Health Status
Heart Failure* / drug therapy
Heart Failure* / ethnology
Humans
Quality of Life*
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
White People

Substances

Sodium-Glucose Transporter 2 Inhibitors